NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
NICE Backs Ruxolitinib Cream Vitiligo Treatment
Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which recommends it for non-segmental vitiligo with facial involvement in people aged 12 and over. This option applies when topical first-line treatments like corticosteroids or calcineurin inhibitors have failed or are unsuitable, subject to a commercial access arrangement. As detailed in NICE’s final guidance, clinical evidence from the TRuE-V1 and TRuE-V2 phase 3 trials shows superior facial repigmentation (F-VASI75 response) and reduced noticeability compared to vehicle cream, despite uncertainties in phototherapy comparisons. Cost-effectiveness analyses using a revised Markov model produce incremental cost-effectiveness ratios (ICERs) below £20,000 per quality-adjusted life year (QALY) gained versus no active treatment followed by phototherapy, supporting routine NHS use within 90 days of publication.
Superior Facial Repigmentation Results
Ruxolitinib cream vitiligo treatment delivers robust efficacy, achieving at least 75% improvement in facial Vitiligo Area Scoring Index (F-VASI75) at week 24, with pooled odds ratios of 4.17 (95% confidence interval 2.43-7.14, p<0.0001) versus vehicle across TRuE-V1 (n=330) and TRuE-V2 (n=344) trials. It also improves Vitiligo Noticeability Scale scores (odds ratio 6.52, 95% confidence interval 3.11-13.67, p<0.0001). These results position it after first-line topicals but before phototherapy for stable non-segmental vitiligo affecting up to 10% body surface area. Indirect comparisons with phototherapy from the HI-Light trial indicate higher overall response rates (25%-100% repigmentation) after 9 months, despite baseline imbalances.
Rigorous Trial Data and Modeling
NICE’s rapid review integrated company submissions, external assessment group critiques, stakeholder inputs, and appeal points after an initial non-recommendation. It focused on ruxolitinib (Opzelura, Incyte) for facial non-segmental vitiligo in those 12 years and over. Methodology from double-blind (24 weeks) and open-label extension phases of TRuE-V trials assessed F-VASI and patient-reported outcomes in intention-to-treat populations (mean 14.8 years since diagnosis). The revised Markov model included seven health states based on F-VASI responses, retreatment, adjusted dosing, and comparators like no active treatment with 25% phototherapy uptake. Uncertainties in non-response permanence, utility mapping from VitiQoL to EQ-5D-3L, and Fitzpatrick subgroup analyses were addressed, aligning with NHS practice.
Cost Savings and Equity Impact
The guidance fits NICE’s ICER range (£20,000-£30,000 per QALY), with base-case results below £20,000 per QALY versus no active treatment plus phototherapy, incorporating EAG adjustments like utility capping and psychological support. It captures benefits as the first licensed topical, easing phototherapy barriers (1-2 year waits, 2-3 weekly sessions for 12 months). It addresses disproportionate impacts on Fitzpatrick 4-6 skin tones and youth. It demonstrates rapid review success for autoimmune dermatoses, with list price discounts (£657/100g tube) aiding reimbursement and real-world evidence on long-term outcomes.
